Pfizer, Inc. has filed two petitions for IPR of Chugai Pharmaceuticals’s patents:  IPR2017-01357 on U.S. Patent 7,332,289 and IPR2017-01358 on U.S. Patent 7,927,815.  According to the petitions, both patents are directed to methods for purifying antibodies.  The petitions do not identify a particular product that may use the patented methods.